Lanreotid Zentiva (Lanreotide)

Lanreotide mimics natural somatostatin and binds primarily to somatostatin receptors SSTR2 and SSTR5. Activation of these receptors inhibits adenylate cyclase, reduces cyclic AMP, and suppresses the release of growth hormone, insulin, glucagon, and various gastrointestinal peptides, thereby controlling hormone‑driven disease processes.

The dose of Lanreotid Zentiva is individualized by the prescribing clinician based on the specific indication, patient characteristics, and response to therapy. Healthcare professionals determine the appropriate amount, dosing interval, and duration of treatment.

Safety data for lanreotide during pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Lanreotid Zentiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

The primary alternative in the same class is octreotide, another somatostatin analog. Both agents inhibit similar hormones, but lanreotide has a longer dosing interval (often every 4 weeks) compared with octreotide, which may require more frequent administration. Choice depends on clinical response, patient preference, and physician judgment.

Lanreotid Zentiva must be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. Keep the product in its original packaging until use to maintain stability and potency.

The medication is supplied as an injectable solution for subcutaneous injection. Administration is typically performed by a healthcare professional in a clinical setting, following aseptic technique and the dosing schedule prescribed by the treating physician.

Serious adverse events to monitor include pancreatitis, severe hyperglycemia or new‑onset diabetes, gallbladder disease such as biliary sludge or gallstones, and cardiac arrhythmias. Patients should be educated to report symptoms like severe abdominal pain, persistent high blood sugar, jaundice, or irregular heartbeats promptly.

Lanreotid Zentiva is contraindicated in individuals with known hypersensitivity to lanreotide or any excipients in the formulation. Caution is advised for patients with severe hepatic impairment, uncontrolled diabetes, or significant cardiac conduction disorders, and it should be avoided in those where the risk outweighs the therapeutic benefit.